Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pantoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 14/20 | 0.52 |
| ▸ | ATP4B known ✓ | P51164 | 14/20 | 0.52 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | FASN | P49327 | 1/20 | 0.52 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.52 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.44 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantoprazole SCHEMBL1476069 | 1.00 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL21986309 | 1.00 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1477291 | 1.00 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL27913225 | 1.00 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL3542 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL6262319 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL5795111 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL3179774 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL4199906 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1560742 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118267481-A | Construction and application of mRNA nano delivery system with environment adaptability and cooperative regulation | 浙江大学 | 2024-07-02 | — | — | CN | claimed |
| CN-114028359-B | Pantoprazole quick-release capsule and preparation method thereof | 厦门恩成制药有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-114028359-A | Pantoprazole quick-release capsule and preparation method thereof | 厦门恩成制药有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-107550871-B | Freeze-dried composition containing pantoprazole sodium | 杭州中美华东制药有限公司 | 2020-07-21 | — | — | CN | claimed |
| CN-111057044-A | Preparation method of single crystal form of pantoprazole sodium sesquihydrate | 北京民康百草医药科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-107550871-A | A kind of freeze-dried composition containing Pantoprazole Sodium | 杭州中美华东制药有限公司 | 2018-01-09 | — | — | CN | claimed |
| CN-104257616-B | A kind of freeze-dried powder injection of pantoprazole sodium and preparation method thereof | 东北制药集团沈阳第制药有限公司 | 2017-07-14 | — | — | CN | claimed |
| CN-105111189-A | Pantoprazole sodium compound monohydrate sphaerocrystal and preparation method thereof | UNIV TIANJIN | 2015-12-02 | — | — | CN | claimed |
| CN-104257616-A | Pantoprazole sodium freeze-dried powder injection and preparation method thereof | NORTHEAST PHARMACEUTICAL GROUP SHENYANG NO 1 PHARMACEUTICAL CO LTD | 2015-01-07 | — | — | CN | claimed |
| US-20100016605-A1 | Process | CIPLA LIMITED (IN) | 2010-01-21 | — | — | US | claimed |
| US-7507829-B2 | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates | TEVA PHARMACEUTICALS INDUSTRIES, LTD (IL) | 2009-03-24 | — | — | US | claimed |
| EP-1901719-A2 | BENZIMIDAZOLE FORMULATION | Nycomed Danmark ApS (DK) | 2008-03-26 | — | — | EP | claimed |
| EP-1895990-A2 | FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS | Combino Pharm, S.L. (ES) | 2008-03-12 | — | — | EP | claimed |
| WO-2007029124-A2 | FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS | COMBINO PHARM, S.L. (US) | 2007-03-15 | — | — | WO | claimed |
| US-20070020334-A1 | Benzimidazole formulation | TAKEDA PHARMA A/S (DK) | 2007-01-25 | — | — | US | claimed |
| WO-2006105798-A2 | BENZIMIDAZOLE FORMULATION | NYCOMED DANMARK APS (DK) | 2006-10-12 | — | — | WO | claimed |
| WO-2006064249-A2 | PROCESS FOR THE PREPARATION OF PANTOPRAZOLE SODIUM | CIPLA LIMITED (IN) | 2006-06-22 | — | — | WO | claimed |
| EP-1572680-A2 | SOLID STATES OF PANTOPRAZOLE SODIUM, KNOWN PANTOPRAZOLE SODIUM HYDRATES, PROCESSES FOR THEIR PREPARATION. | EVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-09-14 | — | — | EP | claimed |
| US-20040177804-A1 | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-09-16 | — | — | US | claimed |
| WO-2004056804-A2 | SOLID STATES OF PANTOPRAZOLE SODIUM, PROCESSES FOR PREPARING THEM AND PROCESSES FOR PREPARING KNOWN PANTOPRAZOLE SODIUM HYDRATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016605-A1 | Process | MPST, HPD, POR | ATP4A 1157/4885ATP4B 598/4885ADRA1A 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.